Almotriptan is a kind of triptan drug which can be used for the
treatment of migraine headaches. It is belong to a drug category of
selective serotonin receptor agonists. It has a high and specificity
affinity for serotonin 5-HT receptors, further leading to
vascoconstriction of the brain blood vessel and affecting the
redistribution of blood flow. These effects stop pain signals from
being sent to the brain, and further suppressing the release of
certain natural substances which cause pain, nausea and other
migraine symptoms. However, it doesn’t prevent migraine attacks.
https://en.wikipedia.org/wiki/Almotriptan
https://www.drugbank.ca/drugs/DB00918
Almotriptan is an agonist of the serotonin (5-HT) receptor subtypes 5-HT1B and 5-HT1D (IC50s = 12 and 13 nM, respectively, in a radioligand binding assay). It is selective for human 5-HT1B and 5-HT1D receptors over rat 5-HT1A and human 5-HT2A and 5-HT4 receptors (IC50s = 0.85, 25.1, and 140 μM, respectively). Almotriptan induces contractions in isolated canine saphenous veins (EC50 = 394 nM) but not isolated rabbit renal or mesenteric arteries. It increases carotid vascular resistance in anesthetized cats (ED100 = 11 μg/kg, i.v.) without increasing blood pressure or heart rate. Formulations containing almotriptan have been used in the treatment of migraine headaches.
Almotriptan is a serotonin 5HT-1B/1D-receptor agonist; antimigraine.
Almotriptan is a serotonin 5HT1B /1D-receptor agonist used for treatment of migraine.
ChEBI: The malate salt of almotriptan.
To a solution of previously dried 1-[[2-carboxy-3-(2-dimethylaminoethyl)-5-
indolyl]methanesulphonyl]-pyrrolidine (1.6 g; 0.0442 moles) in anhydrous
quinoline (75 ml) and under atmosphere of nitrogen, cuprous oxide (160 mg;
0.0011 moles) was added. The reaction mixture was heated to 190°C for 15
minutes, stirred to room temperature, poured into a mixture of 1 N
hydrochloric acid (150 ml) and ethyl acetate (50 ml), shaken and decanted.
The aqueous solution was washed several times with ethyl acetate, then solid
sodium bicarbonate was added until pH = 7.8, and washed with n-hexane to
eliminate the quinoline. The aqueous solution was made alkaline with solid
potassium carbonate and extracted with ethyl acetate. The organic solution
was dried (Na2SO4), the solvent removed under reduced pressure when a
dark oil was obtained (1.3 g; yield 92%). This product was purified by column
chromatography with silica gel and methylene chloride:ethanol:ammonium
hydroxide (60:8:1) as eluent and a white foam (0.8 g) of 1-[[3-(2-
dimethylaminoethyl)-5-indolyl]methanesulphonyl]-pyrrolidine was obtained. To
a solution of the above product (0.8 g) in acetone (30 ml), a few drops of
hydrogen chloride saturated dioxan solution, were added. The precipitated
solid was collected by filtration, washed with acetone and dried to give 1-[(3-
(2-(dimethylamino)ethyl)-5-indolyl)methanesulphonyl]-pyrrolidine
hydrochloride (0.75 g). Melting point 218°-220°C.
In practice it is usually used as malate salt.
Almotriptan, marketed in 2000, has the highest oralbioavailability among all triptans. It is metabolizedby both MAO-A and CYP3A4, thus has a more favorableside effects profile when compared with sumatriptan.However, it is only available in a 12.5 mg tablet form.
Almotriptan is a serotonin 5HT-1B/1D-receptor agonist used to treat migraine. Almotriptan has low nanomolar affinity for the 5-HT(1B) and 5-HT(1D) receptors while affinity for 5-HT receptors other than 5-HT(1B/1D) is substantially lower. Affinity for 5-HT(7) and 5-HT(1A) receptors was approximately 40 and 60 times lower than that for 5-HT(1B/1D) receptors, respectively.
[1] Patent: WO2010/113183, 2010, A2. Location in patent: Page/Page column 26
[2] Patent: WO2008/151584, 2008, A1. Location in patent: Page/Page column 4; 11-12
[3] Patent: EP2774605, 2014, A1. Location in patent: Paragraph 0107
[4] Patent: WO2009/16414, 2009, A1. Location in patent: Page/Page column 13-15; 19-20
[5] Patent: US2007/112055, 2007, A1. Location in patent: Page/Page column 7
